Skip to content

Efficacy and cost-utility assessment of transarterial intervention for unresectable intermediate and advanced hepatocellular carcinoma

Efficacy and cost-utility assessment of transarterial intervention for unresectable intermediate and advanced hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083230
Enrollment
Unknown
Registered
2024-04-18
Start date
2022-09-28
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

exposure group 1:DEB-TACE
exposure group 2:HAIC

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: ? Pathologically diagnosed with hepatocellular carcinoma; ? Aged =18 years old; ? At least one measurable lesion; ? Receiving transarterial intervention for the first time; ? Ineligible for hepatic resection, liver transplantation or local ablation, or refuse the above treatments; ? BCLC B or C stage; ? ECOG PS score of 0-2; ? Liver function of Child-Pugh A or B; ? Consent to receive transarterial intervention.

Exclusion criteria

Exclusion criteria: ? Receiving other anti-tumor therapy; ? Being pregnant or breastfeeding; ? Suffering from psycho-neurological disorder; ? Irreversible coagulation disorders, hemophilia, and poor vascular conditions; ? Greater than 50% liver involvement; ? Complete obstruction of the main portal vein or symptoms of portal hypertension or reflux; ? Localized combined severe infections; ? Symptoms of organ failure; ? Large amounts of ascites with oliguria or anuria.

Design outcomes

Primary

MeasureTime frame
Death;Complete response;Partial response;Stable disease;Progressive disease;

Secondary

MeasureTime frame
quality of life;depressive symptoms;anxiety symptoms;family function;

Countries

China

Contacts

Public ContactKetao Mu

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

muketao@tjh.tjmu.edu.cn+86 189 7162 2511

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026